2024-01-25 10:57:50 ET
Summary
- More than one year into the Launch of Zynteglo and Skysona, BLUE's sales remain underwhelming.
- The company launched a third gene therapy, Lyfgenia, but faces similar commercialization challenges.
- High treatment costs, limited patient base, outsourced production, long-term follow-up studies, and intensifying competition are all factors that obscure BLUE's path to profitability.
Investment Thesis
Our previous article published last year cautioned that significant financial risks overshadow bluebird bio, Inc.'s ( BLUE ) innovative gene therapies. In early 2023, the Massachusetts-based biotech company launched two orphan drugs: Zynteglo for Transfusion-Dependent B-thalassemia 'TDT' and Skysona for Cerebral Adrenoleukodystrophy 'CALD.' ...
Read the full article on Seeking Alpha
For further details see:
Bluebird Bio: Innovative Therapies, Monetary Setbacks